AR072059A1 - Forma de dosificacion farmaceutica en capsula que comprende una formulacion en suspension de un derivado de indolinona - Google Patents

Forma de dosificacion farmaceutica en capsula que comprende una formulacion en suspension de un derivado de indolinona

Info

Publication number
AR072059A1
AR072059A1 ARP090102039A ARP090102039A AR072059A1 AR 072059 A1 AR072059 A1 AR 072059A1 AR P090102039 A ARP090102039 A AR P090102039A AR P090102039 A ARP090102039 A AR P090102039A AR 072059 A1 AR072059 A1 AR 072059A1
Authority
AR
Argentina
Prior art keywords
formulation
suspension
capsule
dosage form
pharmaceutical dosage
Prior art date
Application number
ARP090102039A
Other languages
English (en)
Inventor
Roman Messerschmid
Rudolf Binder
Thomas Bock
Werner Brox
Original Assignee
Boehringer Ingelheim Int
R P Scherer Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40911908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR072059(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int, R P Scherer Gmbh & Co Kg filed Critical Boehringer Ingelheim Int
Publication of AR072059A1 publication Critical patent/AR072059A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • A61K9/4825Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5052Proteins, e.g. albumin
    • A61K9/5057Gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Una formulacion en suspension que contiene la sustancia activa 3-Z-[1-(4-(N-((4-metil-piperazin-1-il)-metilcarbonil)-N-metil-amino)-anilino)-1-fenil-metilen]-6-metoxicarbonil-2-indolinona-monoetanosulfonato, a una forma de dosificacion farmaceutica en c psula que contiene dicha formulacion en suspension, a un procedimiento para preparar dicha formulacion en suspension, a un procedimiento para preparar dicha c psula que comprende dicha formulacion en suspension y el material de embalaje para la c psula terminada. Reivindicacion 16: Formulacion de acuerdo con una cualquiera de las reivindicaciones 1 a 10 o c psula de acuerdo con una cualquiera de las reivindicaciones 11 a 14 caracterizada porque es para uso como composicion farmaceutica con una actividad antiproliferativa. Reivindicacion 17: Formulacion de acuerdo con una cualquiera de las reivindicaciones 1 a 10 o c psula de acuerdo con una cualquiera de las reivindicaciones 11 a 14 caracterizada porque es para el tratamiento de una enfermedad o estado elegido entre enfermedades oncologicas, enfermedades inmunologicas o estados patologicos que implican un componente inmunologico, y enfermedades fibroticas.
ARP090102039A 2008-06-06 2009-06-05 Forma de dosificacion farmaceutica en capsula que comprende una formulacion en suspension de un derivado de indolinona AR072059A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08157748 2008-06-06

Publications (1)

Publication Number Publication Date
AR072059A1 true AR072059A1 (es) 2010-08-04

Family

ID=40911908

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102039A AR072059A1 (es) 2008-06-06 2009-06-05 Forma de dosificacion farmaceutica en capsula que comprende una formulacion en suspension de un derivado de indolinona

Country Status (35)

Country Link
US (4) US20110301177A1 (es)
EP (1) EP2299987B1 (es)
JP (2) JP5661031B2 (es)
KR (2) KR101725469B1 (es)
CN (2) CN105193720B (es)
AR (1) AR072059A1 (es)
AU (1) AU2009254548B2 (es)
BR (1) BRPI0913434B8 (es)
CA (1) CA2726267C (es)
CL (1) CL2010001279A1 (es)
CO (1) CO6280467A2 (es)
CY (1) CY1120533T1 (es)
DK (1) DK2299987T3 (es)
EA (1) EA029996B1 (es)
EC (1) ECSP10010660A (es)
ES (1) ES2669469T3 (es)
HR (1) HRP20180709T1 (es)
HU (1) HUE039187T2 (es)
IL (1) IL208954A (es)
LT (1) LT2299987T (es)
MA (1) MA32385B1 (es)
MX (2) MX2010013203A (es)
MY (1) MY158930A (es)
NO (1) NO2299987T3 (es)
NZ (1) NZ603162A (es)
PE (1) PE20100254A1 (es)
PL (1) PL2299987T3 (es)
PT (1) PT2299987T (es)
RS (1) RS57142B1 (es)
SI (1) SI2299987T1 (es)
TW (1) TW201002691A (es)
UA (1) UA104590C2 (es)
UY (1) UY31879A (es)
WO (1) WO2009147212A1 (es)
ZA (1) ZA201007636B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2299987T (lt) 2008-06-06 2018-05-25 Boehringer Ingelheim International Gmbh Farmacinės vaisto formos kapsulė, apimanti indolinono darinio suspensijos kompoziciją
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
UA107560C2 (uk) * 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
JO3659B1 (ar) * 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
DK2575784T3 (en) 2010-06-02 2018-10-15 Astellas Deutschland Gmbh ORAL DOSAGE FORMS OF BENDAMUSTIN
GB201020032D0 (en) * 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
BR112015006363A2 (pt) 2012-09-28 2017-08-08 Boehringer Ingelheim Int combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
US20150209360A1 (en) * 2014-01-30 2015-07-30 Orbz, Llc Oral caffeine delivery composition
CN112156081A (zh) * 2015-03-13 2021-01-01 江苏豪森药业集团有限公司 含有吲哚满酮衍生物混悬液的药物制剂及其制备方法
CN107019697A (zh) * 2016-02-02 2017-08-08 瑞阳(苏州)生物科技有限公司 预防或治疗纤维化疾病的药物组合物及其应用
WO2018080795A1 (en) * 2016-10-25 2018-05-03 Glykon Technologies Group, Llc Hydroxycitric acid compounds and capsule liquid delivery
CN108066343A (zh) * 2016-11-08 2018-05-25 瑞阳(苏州)生物科技有限公司 一种预防或治疗肾纤维化疾病的药物
WO2018108669A1 (en) 2016-12-12 2018-06-21 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol
WO2018177893A1 (en) 2017-03-28 2018-10-04 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of muscular dystrophy
CN107184549B (zh) * 2017-04-11 2020-11-20 江苏大学 一种尼达尼布自微乳制剂和其制成的软胶囊及制备方法
AU2018357775B2 (en) 2017-10-23 2024-02-15 Boehringer Ingelheim International Gmbh New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
WO2019106692A1 (en) * 2017-11-29 2019-06-06 Sun Pharmaceutical Industries Limited Oral suspension of nintedanib esylate
WO2019173653A1 (en) 2018-03-07 2019-09-12 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
TWI815137B (zh) 2018-06-15 2023-09-11 漢達生技醫藥股份有限公司 尼洛替尼十二烷基硫酸鹽之結晶
CN113301884A (zh) * 2018-09-13 2021-08-24 夫特弗制药私人有限公司 非水性化疗口服悬浮液
CN113164402A (zh) * 2018-10-15 2021-07-23 希普拉有限公司 药物制剂
CN112386580B (zh) * 2019-08-13 2022-07-08 齐鲁制药有限公司 具有改善的溶出度和稳定性的尼达尼布药物制剂、制备方法及其应用
JP2023504415A (ja) 2019-12-04 2023-02-03 イドーシア ファーマシューティカルズ リミテッド 線維性疾患の治療に使用するためのアゼチジンlpa1受容体アンタゴニストのピルフェニドン及び/又はニンテダニブとの合剤
WO2021198253A1 (en) 2020-04-01 2021-10-07 Boehringer Ingelheim International Gmbh Use of biomarkers in the treatment of fibrotic conditions
EP4098246A1 (en) 2021-05-31 2022-12-07 Lotus Pharmaceutical Co., Ltd. Formulation of nintedanib
CN114404382B (zh) * 2022-01-24 2023-05-12 南京康川济医药科技有限公司 乙磺酸尼达尼布软胶囊及其制备方法
WO2023161668A1 (en) 2022-02-28 2023-08-31 Nuformix Technologies Limited Compositions and methods for treatment of idiopathic pulmonary fibrosis
WO2024037982A1 (en) 2022-08-16 2024-02-22 Boehringer Ingelheim International Gmbh Pharmaceutical formulations of nintedanib for intraocular use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2870062A (en) 1956-04-27 1959-01-20 Scherer Corp R P Gelatin composition for capsules
GB8305693D0 (en) 1983-03-02 1983-04-07 Scherer Ltd R P Pharmaceutical compositions
DE3579384D1 (de) 1984-07-24 1990-10-04 Scherer Gmbh R P Oxytetracyclin-hc1-weichgelatinekapseln und verfahren zu ihrer herstellung.
GB9313329D0 (en) * 1993-06-28 1993-08-11 Scherer Ltd R P Softgel capsule shell compositions
DE19603402A1 (de) 1995-02-24 1996-08-29 Basf Ag Weichgelatinekapseln
US6762180B1 (en) 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
CZ20032959A3 (cs) * 2001-05-01 2004-01-14 Pfizer Products Inc. Způsob přípravy farmaceutické kompozice s nízkou dávkou léčiva mající rovnoměrnou distribuci a účinnost léčiva
DE10233500A1 (de) 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
PE20060777A1 (es) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
US20060293260A1 (en) * 2005-05-24 2006-12-28 Wyeth Useful high load concentrate compositions for control of ecto-and endo-parasites
EP1948180B1 (en) * 2005-11-11 2013-03-13 Boehringer Ingelheim International GmbH Combination treatment of cancer comprising egfr/her2 inhibitors
UA107560C2 (uk) 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
KR101760657B1 (ko) * 2008-06-06 2017-07-24 베링거 인겔하임 인터내셔날 게엠베하 약제학적 병용물
LT2299987T (lt) 2008-06-06 2018-05-25 Boehringer Ingelheim International Gmbh Farmacinės vaisto formos kapsulė, apimanti indolinono darinio suspensijos kompoziciją
US20120157472A1 (en) 2009-01-14 2012-06-21 Boehringer Ingelheim International Gmbh Method for treating colorectal cancer
US8802384B2 (en) 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
JP2012526766A (ja) 2009-05-14 2012-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 腫瘍性及び線維性疾患の処置における新規な併用療法

Also Published As

Publication number Publication date
ECSP10010660A (es) 2011-02-28
KR101725469B1 (ko) 2017-04-11
US20110301177A1 (en) 2011-12-08
PL2299987T3 (pl) 2018-08-31
LT2299987T (lt) 2018-05-25
JP5661031B2 (ja) 2015-01-28
CA2726267C (en) 2017-10-31
EP2299987A1 (en) 2011-03-30
TW201002691A (en) 2010-01-16
CN105193720A (zh) 2015-12-30
SI2299987T1 (en) 2018-06-29
CA2726267A1 (en) 2009-12-10
US9907756B2 (en) 2018-03-06
US20140004187A1 (en) 2014-01-02
US20160324791A1 (en) 2016-11-10
CL2010001279A1 (es) 2011-05-13
WO2009147212A1 (en) 2009-12-10
MY158930A (en) 2016-11-30
BRPI0913434B8 (pt) 2021-05-25
DK2299987T3 (en) 2018-05-22
UA104590C2 (ru) 2014-02-25
EA201001856A1 (ru) 2011-06-30
CN102056598A (zh) 2011-05-11
EA029996B1 (ru) 2018-06-29
CN102056598B (zh) 2017-09-19
KR20170020557A (ko) 2017-02-22
NO2299987T3 (es) 2018-07-21
JP2014208712A (ja) 2014-11-06
CY1120533T1 (el) 2019-07-10
BRPI0913434A2 (pt) 2015-12-01
AU2009254548B2 (en) 2015-10-01
IL208954A0 (en) 2011-01-31
UY31879A (es) 2010-01-29
MA32385B1 (fr) 2011-06-01
MX359229B (es) 2018-09-20
AU2009254548A1 (en) 2009-12-10
JP5905542B2 (ja) 2016-04-20
US20160022672A1 (en) 2016-01-28
ES2669469T3 (es) 2018-05-25
KR20110017872A (ko) 2011-02-22
ZA201007636B (en) 2011-08-31
HRP20180709T1 (hr) 2018-06-15
CN105193720B (zh) 2018-07-31
HUE039187T2 (hu) 2018-12-28
EP2299987B1 (en) 2018-02-21
JP2011522812A (ja) 2011-08-04
CO6280467A2 (es) 2011-05-20
RS57142B1 (sr) 2018-07-31
IL208954A (en) 2017-11-30
BRPI0913434B1 (pt) 2020-10-13
PE20100254A1 (es) 2010-04-21
NZ603162A (en) 2014-05-30
MX2010013203A (es) 2011-02-25
PT2299987T (pt) 2018-05-21

Similar Documents

Publication Publication Date Title
AR072059A1 (es) Forma de dosificacion farmaceutica en capsula que comprende una formulacion en suspension de un derivado de indolinona
CL2010001362A1 (es) Forma de dosificacion farmaceutica para la liberacion inmediata de la sustancia activa 3-z-[1-(4-(n-((4-metil-piperazin-1-il)-metilcarbonil)-n-metil-amino)-anilino)-1-fenil-metileno]-6-metoxicarbonil-2-indolinona-monoetanosulfonato; y su uso para el tratamiento y/o prevencion de enfermedades oncologicas e inmunologicas, entre otras.
UY30477A1 (es) Derivados de [4,5']bipirimidinil-6,4´-diamina como inhibidores de cinasa de proteina
Ludka et al. Involvement of PI3K/Akt/GSK-3β and mTOR in the antidepressant-like effect of atorvastatin in mice
PE20150998A1 (es) Inhibidores de histona demetilasas
NI201200029A (es) Compuestos y composiciones como inhibidores de cinasa de proteína
EA201001577A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
EA200901583A1 (ru) N-(2-(гетарил)арил)арилсульфонамиды и n-(2-(гетарил)гетарил)арилсульфонамиды
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
CL2008002793A1 (es) Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
CL2008001465A1 (es) Compuestos derivados de [2,1,3]benzoxadiazol-5-carboxamidas, moduladores de los receptores ampa; composiciones farmacéuticas; y su uso en el tratamiento de afecciones hipoglutamatérgicas, trastornos cognitivos, enfermedad de parkinson, adhd, síndrome de rett, depresión respiratoria, síndrome x frágil y enfermedad de alzheimer.
BR112014032734A2 (pt) derivados de pirrolidina e seu uso como moduladores da série de reação de complemento
DOP2012000025A (es) Derivados de piridina y pirazina como moduladores de cinasa de proteina
GT200600096A (es) Composicion farmaceutica para el tratamiento del cancer
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
CU20110088A7 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
UY31790A (es) Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona
CL2008001766A1 (es) Forma cristalina a y b de 3-(2r-tetrahidrofuril-metil)-2-tioxantina; inhibidor de mieloperoxidasa; procesos para su preparación; formulación farmacéutica que las comprende; y uso en el tratamiento de trastornos neuroinflamatorios,trastornos ateroscleroticos cardio y cerebrovasculares, insuficiencia cardiaca, bronquitis.
BR112015007991A2 (pt) derivados de etinila como moduladores da atividade do receptor de mglur5
AR089112A1 (es) Asociacion entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un antagonista de los receptores nmda y las composiciones farmaceuticas que la contienen
ES2549106T1 (es) Composiciones farmacéuticas que comprenden anagrelida
RU2015150388A (ru) Тартратная соль [(s)-2-[метил-3-(2-оксо-пирролидин-1-ил)-бензолсульфониламино]-3-(4-метил-пиперазин-1-ил)-3-оксо-пропил]амида 5-хлор-тиофен-2-карбоновой кислоты
TH136967A (th) องค์ประกอบให้การก่อกระตุ้นการผลิตลามินิน-332
UY29289A1 (es) Forma de dosificación sólida que comprende un inhibidor de la bomba de protones y una suspensión obtenida a partir de la misma

Legal Events

Date Code Title Description
FB Suspension of granting procedure